Primary Aldosteronism: Superselective Embolization vs. Laparoscopic Endocrine Curative Therapy
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-60
SponsorXinjiang Medical University
About this trial
The aim of this study was to compare the efficacy and safety of adrenalectomy and superselective adrenal artery embolization in a prospective, multicenter, randomized controlled study. To provide a new interventional alternative therapy for primary aldosteronism.
Eligibility criteria
Qualifiers
Age 18-60
Diagnosed with primary aldosteronism according to the 2016 Clinical guidelines of the International Endocrine Society
Primary aldosteronism diagnosed according to international guidelines Unilateral disease by AVS or PET-CT criteria
Patients and their family members signed informed consent and agreed to participate in the study
Disqualifiers
A history of severe hypersensitivity to contrast media
Severe liver disease complications, such as thrombocytopenia, esophageal varices rupture bleeding, etc
Renal insufficiency (serum creatinine > 176mmol/L or estimated glomerular filtration rate < min.1.73m2)
Combined with other secondary hypertension, such as pheochromocytoma, hypercortisolism, renal vascular hypertension (such as renal artery stenosis), renin secretory tumor, renal parenchymatous hypertension, drug-induced hypertension (such as long-term use of glucocorticoids, contraceptives, estrogen, herbal medicines containing glycyrrhizin), pregnancy hypertension and other secondary hypertension
Trial design
Treatments tested in this trial
- Superselective adrenal artery embolization or adrenalectomy
Treatment groups
570 Participants
are divided into 2 treatment groupsSponsors and collaborators
Xinjiang Medical University
Lead sponsor
First Affiliated Hospital of Xinjiang Medical University
Collaborator
Source ClinicalTrials.gov